CONTENTS

1. INTRODUCTION **1-16**

1.1. Targets and treatments in the management of hypertension 1

1.1.1. Sympathetic nervous system (SNS) 1

1.1.2. Renin-angiotensin system (RAS) 1

1.1.3. Kidneys 3

1.1.4. Calcium channels 3

1.1.5. Aldosterone 3

1.1.6. Nitric oxide (NO) 3

1.1.7. Endothelin (EN) 3

1.2. Fixed dose combinations (FDCs) 5

1.3. Development of Multiple target-directed ligands 6

1.4. Rational approaches to design multitarget-directed ligands 6

1.4.1. Dual α_1- and β_1-antagonists 8

1.4.2. β_1-Blockers with NO vasodilatory effect/endothelial β_2-receptor stimulation 8

1.4.3. Dual CCBs and α_1-antagonists 8

1.4.4. Neutral endopeptidase (NEP) inhibitors 9

1.4.5. Dual inhibitors of vasopeptidases (ACE and NEP) 10

1.4.6. Triple vasopeptide inhibitors 12

1.4.7. Dual antagonism of AT_1- and AT_2-receptors 12

1.4.8. AII and ET-1 Inhibitors 14

1.4.9. AII receptors antagonism along with PPAR-γ activation 14

1.4.10. Dual antagonists for the α_1- and AT_1-receptors 16

2. REVIEW OF LITERATURE **17-41**

2.1. AT_1- and α_1-receptors and their antagonism 17

2.2. Dual acting agents used in cardiovascular disorders 19

2.2.1. AT_1- and ET_A-receptor antagonists 19

2.2.2. Combined targeting for AT_1-receptor and NEP 21

2.2.3. AT_1-Antagonism along with PPAR-γ activation 22

2.2.4. Dual antagonism through α_1-receptor/calcium channel blockers 23

2.2.5. Dual inhibition of ACE and NEP 26

2.2.6. Dual inhibition of NEP and ECE 27

2.2.7. Combined antagonism for ET_A- and ET_B-receptors 28

2.2.8. Simultaneous inhibition of ACE, renin and aldosterone 29

2.2.9. α-Adrenoceptors (α_1) antagonism along with β_1, β_2 and β_3 modulating effects 31

2.2.10. Multiple antagonism for α_1-receptor subtypes 31

2.2.11. AT_1-antagonism along with antioxidant activity 33

2.2.12. Dual effects through NaCl reabsorption and vasodilation 36

2.2.13. Platelets anti-aggregation along with antioxidant activity 37

2.2.14. Dual α_1 and 5-HT_{1A}- antagonisms 38

2.2.15. AT_1 and AT_2- receptor antagonists 40

2.2.16. Dual effects through NO mediated vasodilation and $PGF_{2\alpha}$ inhibition 41

3. AIMS AND OBJECTIVES **42-44**

4. RESULTS AND DISCUSSION **45-94**

4.1. Chemical studies 45

4.1.1. Synthesis of starting materials and intermediates 46

4.1.2. Synthesis of 4-amino-2-choloromethyl-6,7-dimethoxyquinazoline and 4-amino-2-choloroethyl-6,7-dimethoxyquinazoline 50

4.1.3. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl)methyl-6,7-dimethoxyquinazolines (**Series I**) 51

4.1.4. Synthesis of 4-amino-2-(1-substituted piperidin-4-ylamino)methyl-6,7-dimethoxyquinazolines (**Series II**) 62

4.1.5. Synthesis of 4-amino-2-(2'/4'-substituted 1,1'-biphenyl-4-ylamino) methyl-6,7-dimethoxyquinazolines (**Series III**) 65

4.1.6. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl)ethyl-6,7-dimethoxyquinazolines (**Series IV**) 68

4.1.7. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl)methyl-6,7-methylenedioxyquinazolines (**Series V**) 71

4.1.8. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl)methyl-7,8-dimethoxyquinazolines (**Series VI**) 78

4.1.9. Synthesis of 2-(4-substituted piperazin-1-yl)methyl-7,8-dimethoxy quinazolin-4(3*H*)-ones (**Series VII**) 86

4.2. Biological activity 91

4.2.1. *In vitro* functional antagonism assay 91

4.2.2. Invasive blood pressure response 93

5. EXPERIMENTAL **95-160**

5.1. Chemical work 95

5.1.1. General Methods 95

5.1.2. Synthesis of starting materials and intermediates 95

- Synthesis of 2-amino-4,5-dimethoxybenzonitrile (**132**) 95
- Synthesis of 2-amino-4,5-methylenedioxybenzonitrile (**138**) 98
- Synthesis of 2-amino-3,4-dimethoxybenzonitrile (**145**) 99
- Synthesis of 2'/4'-substituted *N*-benzylpiperidine-4-carboxamides (**146-151**) 108
- Synthesis of 2'/4'-substituted *N*-benzylpiperidin-4-amines (**152-157**) 110
- Synthesis of substituted 4-amino-1,1'-biphenyls (**158-163**) 112

5.1.3. Synthesis of 4-amino-2-choloromethyl-6,7-dimethoxyquinazoline (**164**) and 4-amino-6,7-dimethoxy-2-vinylquinazoline (**166**) 113

5.1.4. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl) methyl-6,7-dimethoxyquinazolines (**167-192**) (**Series I**) 114

5.1.5. Synthesis of 4-amino-2-(1-substituted piperidin-4-ylamino)methyl-6,7-dimethoxyquinazolines (**193-198**) (**Series II**) 127

5.1.6. Synthesis of 4-amino-2-(2'/4'-substitued 1,1'-biphenyl-4-ylamino) methyl-6,7-dimethoxyquinazolines (**199-204**) (**Series III**) 130

5.1.7. Synthesis of 4-amino-2-(4-substituted piperazin-1-yl)ethyl-6,7-dimethoxyquinazolines (**205-210**) (**Series IV**) 133

5.1.8. Synthesis of 4-amino-2-chloromethyl-6,7-methylenedioxyquinazoline (**192**) & 4-amino-2-(4-substituted piperazin-1-yl)methyl-6,7-methylenedioxyquinazolines (**212-228**) (**Series V**) 135

5.1.9. Synthesis of 4-amino-2-chloromethyl-7,8-dimethoxyquinazoline (**229**) & 4-amino-2-(4-substituted piperazin-1-yl)methyl-7,8-dimethoxyquinazolines (**230-242**) (**Series VI**) 145

5.1.10. Synthesis of 2-chloromethyl-7,8-dimethoxyquinazolin-4(3*H*)-one (**244**) & 2-(4-substituted piperazin-1-yl)methyl-7,8-dimethoxyquinazolin-4(3*H*)-ones (**245-251**) (**Series VII**) 153

5.2. Biological Work 158

5.2.1. Functional antagonism assay on rat aortic strip 158

5.2.2. Invasive measurement of blood pressure 159

6. REFERENCES **161-170**